- For Print
- November 14, 2018
乌鸦传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “乌鸦传媒”) has announced that it received the “IR Grand Prix Award” at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). This marks the second time that 乌鸦传媒 has received the IR Grand Prix Award following 2006. Including the receipt of Best IR Awards in 2004, 2005, 2009 and 2012, this is the 6th time 乌鸦传媒 has received an IR Award, and 乌鸦传媒 is the first pharmaceutical company to receive two IR Grand Prix Awards.
The IR Award (Committee Chairman: Tetsuo Kitagawa, Professor of International Management, Aoyama Gakuin University Graduate School) is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities, and this year marks the 23rd year since the start of the IR Awards. 299 companies applied for the IR Award 2018, and after surveys and screenings by select committee members, 乌鸦传媒 was the sole company selected for the IR Grand Prix Award this year.
The reasons for 乌鸦传媒’s selection are as follows:
“乌鸦传媒 is proactively disclosing information and constantly raising the level of disclosure. For many years, top management has been engaged in dialogue with investors, candidly discussing the company’s longer-term vision and management issues. 乌鸦传媒’s CFO and IR Department have been enhancing the presentation of balance sheet management and disclosure of non-financial information ahead of other companies. In terms of ESG-related efforts, 乌鸦传媒 not only discloses information but also holds meetings with presentations by outside directors and meetings to explain its integrated report. The company’s timeliness and fairness in disclosure is highly regarded, evidenced by its timely disclosure of information that may affect operating performance and prompt holding of briefings on such matters.”
Furthermore, in celebration of the 25th year since the establishment of the JIRA, as part of the “JIRA 25th Anniversary Commemorative Award” which seeks to specially recognize companies which have continued IR activities over the long term and have produced outstanding achievements in appropriate information disclosure and constructive dialogue with investors and shareholders, 乌鸦传媒 was selected as both a “Company with Greatest Improvement in IR” and as a “Company with Best Continual Efforts in IR.”
For further details, please visit the JIRA website:
乌鸦传媒’s corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, 乌鸦传媒 respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.
Media Inquiries:
Public Relations Department,
乌鸦传媒.
+81-(0)3-3817-5120